Shang Hai Zheng Quan Bao·2025-09-15 19:39Core Viewpoint - The controlling shareholder of Shanghai Pharmaceuticals, Shanghai Shiyuan Group, plans to increase its stake in the company through its wholly-owned subsidiary, Shanghai Shiyuan International Investment Co., Ltd. [2][3] Group 1: Basic Information of the Increasing Entity - The increasing entity, Shanghai Shiyuan International Investment Co., Ltd., is a wholly-owned subsidiary of Shanghai Shiyuan Group, which is the controlling shareholder of Shanghai Pharmaceuticals [2]. - After the recent purchase of 100,000 H-shares on September 15, 2025, Shanghai Shiyuan International now holds 300,538,000 H-shares, accounting for 8.104% of the total share capital of the company [2]. Group 2: Main Content of the Increasing Plan - The controlling shareholder, Shanghai Shiyuan Group, plans to increase its stake through Shanghai Shiyuan International by acquiring between 55 million to 74 million H-shares over the next 12 months, not exceeding 2% of the company's voting shares [3]. - The increase will be executed through the Hong Kong Stock Exchange's centralized bidding system, with no fixed price range set for the purchases, allowing for flexibility based on market conditions [3]. Group 3: Other Relevant Information - The increasing plan complies with the relevant laws and regulations, including the Securities Law of the People's Republic of China and the Hong Kong Securities and Futures Commission's rules [7]. - The controlling shareholder and its subsidiaries commit not to reduce their holdings of the company's shares during the implementation of the increasing plan and for six months thereafter [7].